Conference
Abstract CT213:Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)
| العنوان: | Abstract CT213:Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC) |
|---|---|
| المؤلفون: | Planchard, David, Özgüroğlu, Mustafa, Daniel, Davey, Villegas, Augusto, Vicente, David, Murakami, Shuji, Hui, Rina, Faivre-Finn, Corinne, Paz-Ares, Luis, Wu, Yi-Long, Macpherson, Euan, Newton, Michael, Dennis, Phillip, Antonia, Scott J. |
| المصدر: | Planchard , D , Özgüroğlu , M , Daniel , D , Villegas , A , Vicente , D , Murakami , S , Hui , R , Faivre-Finn , C , Paz-Ares , L , Wu , Y-L , Macpherson , E , Newton , M , Dennis , P & Antonia , S J 2020 , ' Abstract CT213 : Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC) ' . https://doi.org/10.1158/1538-7445.am2020-ct213 |
| سنة النشر: | 2020 |
| المجموعة: | The University of Manchester: Research Explorer - Publications |
| مصطلحات موضوعية: | ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre |
| الوصف: | Background: The phase 3 PACIFIC trial established durvalumab (durva) after concurrent chemoradiotherapy (cCRT) as standard of care for unresectable Stage III NSCLC. We report exploratory, post-hoc analyses to assess the impact of smoking status on outcomes in pts from PACIFIC. Methods: PACIFIC was a double-blind trial of pts without disease progression after platinum-based cCRT (≥2 cycles). Pts were randomized 2:1 to receive durva 10 mg/kg or placebo (pbo) intravenously q2w for ≤12 months, stratified by age, sex, and smoking history. Primary endpoints were PFS and OS. Treatment effects (HRs) within subgroups of smokers (current and former) and never smokers were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). Results: Of 713 randomized pts, 64 (9%) were never smokers (Table). Baseline characteristics were broadly well balanced; however, irrespective of study arm, proportionally more never smokers (vs smokers) were female, Asian, and had non-squamous histology. Among never smokers, proportionally more pts in the pbo arm vs durva arm were Stage IIIB (52% vs 40%) and had received induction chemotherapy (33% vs 21%). PFS and OS were improved with durva vs pbo in both smokers and never smokers (Table). The incidence of grade 3/4 AEs was proportionally higher in smokers (vs never smokers) in both the durva (34% vs 23%) and pbo arms (30% vs 14%). In contrast, the incidence of any-grade pneumonitis/radiation pneumonitis was proportionally higher in never smokers (vs smokers) in the durva (56% vs 32% [grade 3/4: 7% vs 3%]) and pbo arms (48% vs 23% [grade 3/4: 5% vs 2%]). |
| نوع الوثيقة: | conference object |
| اللغة: | English |
| DOI: | 10.1158/1538-7445.am2020-ct213 |
| الاتاحة: | https://research.manchester.ac.uk/en/publications/4566ec70-55dd-4a38-9917-cad0fe54f28d https://doi.org/10.1158/1538-7445.am2020-ct213 https://www.mendeley.com/catalogue/2df74177-56d7-33a1-aca4-16e0fba3ff32/ |
| Rights: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.76181B80 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/1538-7445.am2020-ct213 |
|---|